Holen Sie sich die Stockscreener-App
14.06
2.11%
0.29
Schlusskurs vom Vortag:
$13.77
Offen:
$13.69
24-Stunden-Volumen:
124.07K
Relative Volume:
0.56
Marktkapitalisierung:
$526.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.33%
1M Leistung:
+20.38%
6M Leistung:
+12.48%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.51
$14.13
1-Wochen-Bereich:
$13.43
$15.70
52-Wochen-Spanne:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Vergleichen Sie ORKA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
14.06 | 533.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Oruka Therapeutics Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
What analysts say about Oruka Therapeutics Inc. stockExponential return rates - jammulinksnews.com
Is Oruka Therapeutics Inc. a good long term investmentExceptional market positioning - jammulinksnews.com
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial - MSN
Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GlobeNewswire
Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug - Investing.com India
Stifel reiterates Buy rating on Oruka Therapeutics stock with $47 target - Investing.com Canada
Oruka Therapeutics: Revolutionizing Psoriasis Treatment with Extended-Dosing Biologics - AInvest
FDA clears Oruka’s IND for psoriasis drug ORKA-001 phase 2a trial - Investing.com India
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - Yahoo Finance
What drives Oruka Therapeutics Inc. stock priceFree AI-Backed Trading Signals - jammulinksnews.com
How high can Oruka Therapeutics Inc. stock price go in 2025Balanced Risk Reward Portfolio - Newser
How Oruka Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionFree Real-Time Stock Data - Newser
What makes Oruka Therapeutics Inc. stock price move sharplyWeekly Big Movers - Newser
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics announces COO appointment - MSN
Oruka Therapeutics Shares Soar 16.1% on Executive Promotion, Index Inclusion - AInvest
Oruka Therapeutics Promotes Laura Sandler to COO - MarketScreener
Oruka Therapeutics promotes Laura Sandler to chief operating officer - Investing.com
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer - GlobeNewswire
Oruka Therapeutics Appoints New Chief Operating Officer - TipRanks
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000E Index - MarketScreener
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts - Defense World
Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Squarepoint Ops LLC Acquires New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial - MSN
Oruka Therapeutics Holds Annual Stockholders Meeting - TipRanks
Jane Street Group LLC Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):